89 results
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
efficiency and CXCR4 antagonists including APHEXDA (motixafortide) in patients with multiple myeloma. The poster will be presented at the American Society … normal cells in the bone marrow. According to the American Cancer Society, in 2024, it is estimated that more than 35,000 people will be diagnosed
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
Society, in 2024, it is estimated that more than 36,000 people will be diagnosed with multiple myeloma, and nearly 13,000 people will die from the disease … with multiple myeloma. The success of ASCT depends on adequate mobilization of stem cells during the treatment process. The American Society
6-K
EX-99
BLRX
Bioline Rx Ltd
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
Updates
Motixafortide (selective inhibitor of CXCR4 chemokine receptor)
Multiple Myeloma
Presented posters at both the American Society of Hematology
6-K
EX-99
BLRX
Bioline Rx Ltd
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.
American Cancer Society. Key Statistics … for Pancreatic Cancer. Atlanta, Ga: American Cancer Society; 2024.
ASCO Cancer.Net. Editorial Board Approval March 2023.
Contacts:
United States
John
6-K
EX-1
zv6enwjgrd101
16 Feb 24
Current report (foreign)
7:07am
6-K
EX-99
ittoo64glvn7v
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
ppz5n
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
dyr414 k6nszbxvs
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
EX-99
c5q3j t2bhh
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
xrvxi1u2s7 dlb
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
itnp 56lb8hnqagw
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-1
p1hp7x1p 80d
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am
6-K
EX-99
t70v vt892ol
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
la7sp dwzmh9
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
EX-99
2htxv7ps84 3tke8tcfd
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
817sv55
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
vyhnok80qsgaob
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am
424B5
itlemn7mg13t6046
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
wfiunjcomo0 0d
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am